Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases
- 10 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Structural & Molecular Biology
- Vol. 27 (1), 92-104
- https://doi.org/10.1038/s41594-019-0358-z
Abstract
Kinases are involved in disease development and modulation of their activity can be therapeutically beneficial. Drug-resistant mutant kinases are valuable tools in drug discovery efforts, but the prediction of mutants across the kinome is challenging. Here, we generate deep mutational scanning data to identify mutant mammalian kinases that drive resistance to clinically relevant inhibitors. We aggregate these data with subsaturation mutagenesis data and use it to develop, test and validate a framework to prospectively identify residues that mediate kinase activity and drug resistance across the kinome. We validate predicted resistance mutations in CDK4, CDK6, ERK2, EGFR and HER2. Capitalizing on a highly predictable residue, we generate resistance mutations in TBK1, CSNK2A1 and BRAF. Unexpectedly, we uncover a potentially generalizable activation site that mediates drug resistance and confirm its impact in BRAF, EGFR, HER2 and MEK1. We anticipate that the identification of these residues will enable the broad interrogation of the kinome and its inhibitors.Keywords
This publication has 92 references indexed in Scilit:
- EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung AdenocarcinomaClinical Cancer Research, 2012
- Robust rank aggregation for gene list integration and meta-analysisBioinformatics, 2012
- MEK1 mutations confer resistance to MEK and B-RAF inhibitionProceedings of the National Academy of Sciences of the United States of America, 2009
- Activation of tyrosine kinases by mutation of the gatekeeper threonineNature Structural & Molecular Biology, 2008
- Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110αCancer Cell, 2008
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences of the United States of America, 2008
- BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR MutationsPLoS Medicine, 2007
- An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor ReceptorCell, 2006
- UCSF Chimera?A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- MUSCLE: multiple sequence alignment with high accuracy and high throughputNucleic Acids Research, 2004